Skip to main content
Netramark Holdings Inc. logo

Netramark Holdings Inc. — Investor Relations & Filings

Ticker · AIAI ISIN · CA64119M1059 LEI · 391200VOK8WHERIX0Q06 CSE Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 336 across all filing types
Latest filing 2022-05-19 Regulatory Filings
Country CA Canada
Listing CSE AIAI

About Netramark Holdings Inc.

https://www.netramark.com/

Netramark Holdings Inc. develops and deploys advanced Artificial Intelligence (AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry, focusing on optimizing clinical trial design and outcomes. Its core product, NetraAI, is an AI platform powered by the proprietary Attractor AI algorithm. NetraAI analyzes complex, multimodal clinical trial datasets to uncover hidden patient correlations and causal factors, providing high clarity and explainability. The platform delivers AI-powered insights to trial sponsors, clinical research organizations, and biotechnology companies. These insights are used to inform protocol design, identify optimal patient subpopulations, determine effective dosage, enhance enrichment strategies, and improve inclusion/exclusion criteria, thereby increasing effect sizes and minimizing clinical trial risks.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2022-05-19 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a population stratification project by Nurosene Health Inc. for a major pharmaceutical company. It describes the use of proprietary AI technology to analyze clinical trial data and generate insights. The text includes forward-looking statements and contact information but does not contain any financial statements, regulatory filings, or detailed financial data. It is not an annual report, earnings release, management discussion, or any other formal financial or regulatory filing. The document is a corporate announcement about a project completion and technology application, typical of a general regulatory announcement or press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-05-18 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic Master Services Agreement between Nurosene Health Inc. and Cove Neurosciences Inc. It describes the nature of the partnership, the technology involved, and the expected benefits. There are no financial statements, regulatory filings, or detailed financial data presented. The document is not an annual or interim report, earnings release, or any form of financial supplement. It is a corporate announcement about a strategic agreement, which does not fit into categories like M&A, capital update, or management changes. It is a general regulatory announcement about a business development. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-05-06 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the initiation of research collaboration between Nurosene and Dalhousie University, funded by Canada's National Research Council IRAP program. It discusses the research focus on the Nuro App and brain imaging technologies but does not contain any financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any other formal financial or regulatory filing. The content is informational about research activities and funding, typical of a general regulatory announcement or corporate news release. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2022-04-19 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing a research partnership between Nurosene Health Inc. and the Ontario Institute for Cancer Research. It discusses the goals and potential impact of the research collaboration, focusing on pancreatic cancer and the use of AI technology. There are no financial statements, regulatory filings, or detailed financial data presented. The document is informational and promotional in nature, typical of a general corporate announcement or news release. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention the release or availability of a report. Given the content and context, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-04-13 English
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Gino DeMichele to the Board of Directors of Nurosene Health Inc. It focuses on management changes and does not contain financial data, audit information, or report publication details. The key phrase 'appoints Gino DeMichele to the Board of Directors' clearly indicates a change in senior management or board composition. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 4140 characters, which is consistent with a typical announcement rather than a full report. No financial statements or regulatory filings are included.
2022-04-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.